Bethany Jablonski Horton

Dr. Bethany Jablonski Horton


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2016 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
BHBethany Jablonski Horton
Bethany Jablonski Horton
NWNolan Wages
Nolan Wages
MCMark R. Conaway
Mark R. Conaway

16 July 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KRKara D. Romano
Kara D. Romano
CHColin Hill
Colin Hill
DTDaniel Trifiletti
Daniel Trifiletti
MPM. Sean Peach
M. Sean Peach
BHBethany Jablonski Horton
Bethany Jablonski Horton
TSTimothy N. Showalter
Timothy N. Showalter
Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Fifty-six women with FIGO IB1 – IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD2) D2cc was ≥80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD2 D2cc ≥ 65 Gy and seven patients had a sigmoid D2cc ≥ 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.

11 October 2018 in Clinical Trials
Verified
Journal Article
Open access
PDF file
BHBethany Jablonski Horton
Bethany Jablonski Horton
NWNolan A Wages
Nolan A Wages
MCMark R Conaway
Mark R Conaway
Background: Limited options are available for dose-finding clinical trials requiring group-specific dose selection. While conducting parallel trials for groups is an accessible approach to group-specific dose selection, this approach allows for maximum tolerated dose selection that does not align with clinically meaningful group order information. Methods: The two-stage continual reassessment method is developed for dose-finding in studies involving three or more groups where group frailty order is known between some but not all groups, creating a partial order. This is an extension of the existing continual reassessment method shift model for two ordered groups. This method allows for dose selection by group, where maximum tolerated dose selection follows the known frailty order among groups. For example, if a group is known to be the most frail, the recommended maximum tolerated dose for this group should not exceed the maximum tolerated dose recommended for any other group. Results: With limited alternatives for dose-finding in partially ordered groups, this method is compared to two alternatives: (1) an existing method for dose-finding in partially ordered groups which is less computationally accessible and (2) independent trials for each group using the two-stage continual reassessment method. Simulation studies show that when ignoring information on group frailty, using independent continual reassessment method trials by group, 30% of simulations would result in maximum tolerated dose selection that is out of order between groups. In addition, the two-stage continual reassessment method for partially ordered groups selects the maximum tolerated dose more often and assigns more patients to the maximum tolerated dose compared to using independent continual reassessment method trials within each group. Simulation results for the proposed method and the less computationally accessible approach are similar. Conclusion: The proposed continual reassessment method for partially ordered groups ensures appropriate maximum tolerated dose order and improves accuracy of maximum tolerated dose selection, while allowing for trial implementation that is computationally accessible.

9 August 2023 in The Oncologist
Verified
Journal Article
Open access
PDF file
RGRyan D Gentzler
Ryan D Gentzler
LVLiza C Villaruz
Liza C Villaruz
JRJohn C Rhee
John C Rhee
BHBethany Jablonski Horton
Bethany Jablonski Horton
JMJoseph Mock
Joseph Mock
CRCharles M Rudin
Charles M Rudin
Background: CREBBP and EP300 mutations occur at a frequency of 15% and 13%, respectively, in small cell lung cancer (SCLC), and preclinical models demonstrated susceptibility to targeting with HDAC inhibitors. Methods: Patients with treatment-naïve extensive-stage SCLC, ECOG ≤2 were enrolled and treated with entinostat orally weekly (4 dose levels, DL) in combination with standard dose carboplatin, etoposide, and atezolizumab. Cohort allocation was determined by Bayesian optimal interval (BOIN) design targeting an MTD with a DLT rate of 20%. Results: Three patients were enrolled and treated at DL1 with entinostat 2 mg. Patients were aged 69-83; 2 male, 1 female; 2 were ECOG 1, and 1 was ECOG 0. The most common adverse events (AEs) were anemia (3), neutropenia (3), thrombocytopenia (2), leukopenia (2), and hypocalcemia (2). Two experienced DLTs during cycle 1: (1) grade (Gr) 4 febrile neutropenia, and (1) Gr 5 sepsis. BOIN design required stopping accrual to DL1, and the trial was closed to further accrual. Entinostat and atezolizumab pharmacokinetics were both comparable to historical controls. Conclusion: Addition of entinostat to atezolizumab, carboplatin, and etoposide is unsafe and resulted in early onset and severe neutropenia, thrombocytopenia. Further exploration of entinostat with carboplatin, etoposide, and atezolizumab should not be explored. (ClinicalTrials.gov Identifier: NCT04631029).

7 May 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
BHBethany Jablonski Horton
Bethany Jablonski Horton
JOJohn O'QUigley
John O'QUigley
MCMark R Conaway
Mark R Conaway
Patient heterogeneity, in which patients can be grouped by risk of toxicity, is a design challenge in early phase dose finding trials. Carrying out independent trials for each group is a readily available approach for dose finding. However, this often leads to dose recommendations that violate the known order of toxicity risk by group, or reversals in dose recommendation. In this manuscript, trials for partially ordered groups are simulated using four approaches: independent parallel trials using the continual reassessment method (CRM), Bayesian optimal interval design, and 3 + 3 methods, as well as CRM for partially ordered groups. Multiple group order structures are considered, allowing for varying amounts of group frailty order information. These simulations find that parallel trials in the presence of partially ordered groups display a high frequency of trials resulting in reversals. Reversals occur when dose recommendations do not follow known order of toxicity risk by group, such as recommending a higher dose level in a group of patients known to have a higher risk of toxicity. CRM for partially ordered groups eliminates the issue of reversals, and simulation results indicate improved frequency of maximum tolerated dose selection as well as treating a greater proportion of trial patients at this dose compared with parallel trials. When information is available on differences in toxicity risk by patient subgroup, methods designed to account for known group ordering should be considered to avoid reversals in dose recommendations and improve operating characteristics.

22 July 2025 in Pediatric Pulmonology
Verified
Journal Article
Open access
KLKevin P. Lonabaugh
Kevin P. Lonabaugh
ASAnna Saulitis
Anna Saulitis
EBElizabeth Boettinger
Elizabeth Boettinger
DBDavid Brighton
David Brighton
MAMegan Akers
Megan Akers
RLRachel Linnemann
Rachel Linnemann
Background: Despite eligibility of over 90% of people with cystic fibrosis (PwCF) for CFTR modulators, 12% of eligible PwCF are not prescribed these therapies. The CF Foundation CF Learning Network (CFLN) convened a quality improvement (QI) innovation lab (iLab) to investigate gaps in modulator use and identify best practices for modulator initiation, management, and side effect screening. Methods: Thirty‐one CF centers used the Model for Improvement to adapt interventions to local context by Plan‐Do‐Study‐Act cycles and approach aims in two phases: (1) increase documented elexacaftor‐tezacaftor‐ivacaftor or ivacaftor (ETI/I) use or co‐produced deferral by 4% by 5/2023 and (2) increase side effect screening rates for PwCF taking ETI to 80% by 8/2024. Interventions included processes to track eligibility and facilitate safety assessments and tools like screener forms. Centers submitted weekly measures. We used control charts and run charts to analyze progress. Results: Of 4649 PwCF evaluated from 12/2022 to 5/2023, 98.5% on average had documentation of either ETI/I use (89.3%) or deferral (9.2%). The most common reason for deferral was previous side effects (39.0%). Across 3236 visits from 3/2024 to 8/2024, ETI side effect screening rates improved, with the centerline shifting from 67.1% to 80.8%. Potential side effects were identified in 24.5% of screenings, most commonly mood changes, inattention/brain fog, and weight gain. Conclusions: Application of QI methods resulted in processes and tools for enhancing modulator management and improving side effect screening across multiple CFLN centers. Potential side effects, including those not listed in the prescribing information, were commonly reported, highlighting the importance of side effect screening and management by care teams. Interventions can be reproduced by other centers and applied to novel CF therapies.